Pharmidex are delighted to be one of sixteen partners in an EU Horizon 2020 grant - HeatNMof
April 12, 2022

HeatNMof is a heating-triggered drug release from nanometric metal-organic framework composites

The Initial Training Network HeatNMof aims to develop high quality training opportunities for 12 early-stage-researchers (ESRs) in the area of materials science, advanced characterization and biomedicine.


HeatNMof is training the next generation of materials scientists in nanomedicine to exploit heat-triggered release for delivery of anti-tumour drugs. The network is focusing on one of the most promising classes of nanocomposite carriers, inorganic nanoparticles (iNPs) associated to nanoscaled metal organic frameworks (nanoMOFs).


The successful development of this project, involving seven academic, three industrial partners, six partner organisations (5 universities and 1 company), will contribute to the improvement of the highly societal relevant cancer therapy..


Partners: Fundación IMDEA Energía (Coordinator), Universidad de Santiago de Compostela; Centre National de la Recherche Scientifique; Universiteit Antwerpen; Immaterial Labs Ltd; Institut National des Sciences Appliquees de Toulouse; Universitaet Hamburg; Fondazione Istituto Italiano di Tecnologia.; Nanoscale Biomagnetics SL; Isern Patentes Y Marcas M SL.


- Partner Organisations: Universidad Rey Juan Carlos; Universidad de Zaragoza, University of Cambridge; Universite de Nantes; Universita Degli Studi di Genova; Pharmidex.


Funding Institution/Program: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement Nº 860942.


Call: H2020-MSCA-ITN-2019 (ETN)


https://www.energy.imdea.org/research/projects/heatnmof

November 19, 2025
The Pharmidex team will be in London for London Life Sciences Week from the 16th. Janette Dalay Robertson and Ash Alavijeh will be attending a range of events across the week. We are looking forward to a busy week discussing all things life-science related. Get in touch if you’d like to meet with us during the week as we visit existing clients and stakeholders!
November 12, 2025
Our Head of Integrated Therapeutics and CNS, Dr. Stephen Mitchell , our Business Development Manager, Janette Dalay Robertson and our Senior Research Scientist in CNS, Jewel Ahmed will be there to engage with attendees, share insights and explore new collaborations driving innovation in Parkinson’s disease drug discovery and development. If you’re attending, don’t hesitate to reach out, they’ll be delighted to connect and discuss how Pharmidex’s integrated expertise can help move your research from concept to clinic.
November 11, 2025
We are delighted to share that Prof. Mo Alavijeh will be attending the upcoming 🔬 OBN (UK) Ltd BioTuesday: A Spotlight on the Latest R&D for the Diagnosis & Treatment of Prostate Cancer 📅 11 November 2025 📍 Ipsen, Paddington, London This event brings together leading experts and innovators shaping the future of prostate cancer research and therapy. If you’re attending, don’t miss the opportunity to meet with Prof. Mo Alavijeh (FRSC, FRSM), and explore how collaboration can accelerate progress in drug discovery and development.
More Posts